Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-06 00:00:00 ET · period of report 2025-02-04 · accession 0000875320-25-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-06 | 2025-02-04 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | A - Grant | $0.00 | +15.3K | 65.5K | +31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-04 | A | A | 7,114 | $0.00 | 72,647 | D | — | — | (F2) Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. |
| 2 | Common | Common Stock | 2025-02-04 | A | A | 8,210 | $0.00 | 65,533 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. |